Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The patent portfolio for Glaxosmithkline Intellectual Property (No 4) Ltd. is currently active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution is highly focused, involving 1 distinct examiner and 1 distinct art unit. Such a concentrated profile suggests that the current activity is limited to a specific invention or a narrow set of claims within the broader pharmaceutical field.
KIM, YUNSOO is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because this is the only active matter, the examiner's individual review process and technical interpretation will be the sole determinants of the portfolio's immediate progress. The presence of 1 distinct art unit further simplifies the prosecution landscape, allowing practitioners to focus their arguments on the specific standards applied by KIM, YUNSOO in the Biotechnology & Pharmaceuticals sector. This concentration of effort is often beneficial for resolving complex technical issues with a point of contact at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 66.1% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786251 | IGG:TGFBETARII FUSION PROTEIN COMPOSITION | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786251 | IGG:TGFBETARII FUSION PROTEIN COMPOSITION | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17786251 | IGG:TGFBETARII FUSION PROTEIN COMPOSITION | KIM, YUNSOO | 1641 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlaxosmithkline Intellectual Property (No 4) Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Yunsoo Kim has the most, with 1 of Glaxosmithkline Intellectual Property (No 4) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.